ACADIA PHARMACEUTICALS INC.
Headquarters: San Diego
CEO: Stephen Davis
August quarterly results: The company reported $57.1 million in revenue, an 87 percent year-over-year increase. Net loss was listed as $63.3 million.
Stock listing: ACAD on Nasdaq
Company description: Acadia’s Nuplazid was the first approved drug to treat hallucinations and delusions caused by Parkinson’s disease. The company is developing the drug for other indications.
Acadia Pharmaceuticals is flying higher after the U...